AirFluSal MDI (fluticasone propionate salmeterol xinafoate): Reviews and patient testimonials
Back to the list of medications
Medication indications
AirFluSal MDI 25 microgram/125 microgram per actuation pressurised inhalation, suspension
AirFluSal MDI is indicated for use in adults with asthma 18 years of age and older only.
AirFluSal MDI is indicated in the regular treatment of patients with asthma where use of a combination product (long-acting β2 agonist and inhaled corticosteroid) is appropriate:
- patients not adequately controlled on an inhaled corticosteroid and 'as needed' inhaled short-acting β2 agonist
or
- patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist
AirFluSal MDI 25 microgram/250 microgram per actuation pressurised inhalation, suspension
AirFluSal MDI is indicated for use in adults with asthma 18 years of age and older only.
AirFluSal MDI is indicated in the regular treatment of patients with asthma where use of a combination product (long-acting β2 agonist and inhaled corticosteroid) is appropriate:
- patients not adequately controlled on an inhaled corticosteroid and 'as needed' inhaled short-acting β2 agonist
or
- patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist
Route of administration: opinion.traitement.inhalation
Molecule: fluticasone propionate, salmeterol xinafoate
Tips and advice of the community
Join Carenity and be the first to give your opinion on this medication.